Drug intelligence / Profile preview

Multifood

Development stage: Preclinical
Lead developer: Intrommune Therapeutics
Modality: Recombinant Proteins and Enzymes, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Buccal

Overview

Multifood (INT302) is an oral mucosal immunotherapy (OMIT) in development by Intrommune Therapeutics, designed to treat multiple food allergies simultaneously. [1] The product is a toothpaste formulation containing various food allergen proteins. Its mechanism of action is based on the daily application to the oral mucosa, which exposes the immune system to the allergens with the goal of inducing immune tolerance and desensitization. [1] This approach aims to provide a convenient, patient-friendly, and disease-modifying therapy for individuals with multiple food allergies. [1]

Brand names: Multifood

Beyond the preview

Go deeper on Multifood.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multifood.

Explore the full profile